This week Thomas Chittenden of Genuity Science tells Harry about the company's work to use the power of causal statistical learning, Bayesian belief networks, and other advanced math techniques to understand that cascading gene interactions that account for health and disease—and translate them into insights that can provide drug makers with new targets.
The content above was previously recorded. The views herein were made at the time of this recording and are not updated to reflect changes in economic or financial circumstances. The opinions are those of the contributor and not Scientia Ventures, LLC, its affiliates, officers, or employees. Nothing herein constitutes a recommendation, solicitation, or offer to purchase securities or private funds, which can only be made through the relevant offering documents.
